Pulmatrix and Cullgen Collaborate on Strategic Merger Plans
Pulmatrix continues to support Cullgen in seeking approval for their merger from the China Securities Regulatory Commission.
FRAMINGHAM, Mass. — Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company dedicated to the development of innovative inhaled therapeutic solutions for migraines and respiratory diseases, has announced a significant step forward with Cullgen Inc. In light of ongoing regulatory processes, both companies have mutually agreed to waive the "No Solicitation" clause outlined in their existing Merger Agreement, originally signed in November 2024. This decision allows each entity the freedom to explore alternative transactions while still pursuing merger approval from the China Securities Regulatory Commission (the "CSRC").
Peter Ludlum, Interim Chief Executive Officer of Pulmatrix, commented on the matter, stating, "Our Form S-4 filing was declared effective in May 2025, and stockholders approved the merger agreement in June 2025. However, we have not yet obtained CSRC approval. Therefore, we believe it is prudent to explore any opportunistic transactions that could benefit both companies while we continue to seek approval from the regulatory body."
Understanding the Dynamic Merger with Cullgen
In previous reports, it was detailed that Pulmatrix entered into a merger agreement with Cullgen on November 13, 2024. This agreement is subject to a series of amendments, including one from April 7, 2025. The proposed merger has garnered attention due to the companies’ alignment in their therapeutic focuses.
The investors and stakeholders of both companies remain excited about the possible synergies that a merger could create, particularly as both parties aim to enhance their product pipelines in addressing unmet medical needs.
Additional details regarding the merger agreement were disclosed previously in a registration statement on Form S-4, which has gone through several amendments since its initial filing with the Securities and Exchange Commission (the "SEC") in early 2025. As of the latest update, closing the merger will depend on fulfilling specific conditions, including obtaining the necessary approvals and satisfying Nasdaq's listing requirements.
Current Financial Status and Anticipations
As of September 30, 2025, Pulmatrix reported a total cash balance of $4.8 million. The leadership team projects that this cash position, strategically aligned with operational efficiencies and spending prioritization, should sufficiently support operations into at least the fourth quarter of 2026. This ensures that Pulmatrix can continue its pivotal work in advancing its therapeutic candidates while navigating the merger discussions.
Pulmatrix Clinical Development Initiatives
Pulmatrix is committed to leveraging its proprietary iSPERSE™ technology, aimed specifically at improving the efficacy of inhaled therapeutics. This includes a range of clinical assets designed to address key health challenges.
Highlighting Key Products in the Pipeline
iSPERSE™ Technology
The iSPERSE™ technology offers a unique particle formulation that enhances drug delivery effectiveness compared to traditional methods. Currently, Pulmatrix has approximately 146 patents related to this technology, with 18 of those granted in the United States.
Focus on PUR3100 and Other Assets
PUR3100 stands out as a critical asset, designed as an inhaled dihydroergotamine (DHE) to treat acute migraines. It is progressing towards Phase 2 clinical trials following favorable IND application outcomes. Meanwhile, PUR1800 represents another promising candidate aimed at treating acute exacerbations in chronic obstructive pulmonary disease (AECOPD), with ongoing studies reinforcing its safety and efficacy.
Latest on PUR1900
PUR1900 is an antifungal treatment that has seen diversified development. Collaboration with Cipla is set to continue, specifically regarding essential trials outside the United States. As Cipla approaches Phase 3 clinical trials in India, Pulmatrix stands to gain royalties from future sales, solidifying its strategic financial outlook.
About Pulmatrix, Inc.
Pulmatrix is focused on developing innovative inhaled therapies, especially targeting CNS disorders and chronic respiratory diseases through its patented iSPERSE™ technology. The company aims to maximize therapeutic delivery while mitigating side effects, ultimately improving patient outcomes.
Frequently Asked Questions
What is the current status of the Pulmatrix and Cullgen merger?
The companies have waived the no solicitation clause to explore alternative transactions while pursuing regulatory approval.
What financial position does Pulmatrix hold?
Pulmatrix reported a cash balance of $4.8 million as of September 30, 2025, sufficient to support operations into 2026.
What does the iSPERSE™ technology do?
This technology enhances drug delivery via inhalation, potentially improving treatments for various diseases.
What are the key products in development by Pulmatrix?
Key products include PUR3100 for migraines, PUR1800 for AECOPD, and PUR1900 for antifungal applications.
How is Pulmatrix addressing its future?
Pulmatrix is focused on optimizing its clinical assets while navigating the complexities of its merger with Cullgen.
